MBX Biosciences, Inc.

Last week, we held a company-wide virtual meeting with Patty Keating, Executive Director, and Michele Rayes, Associate Director, of the HypoPARAthyroidism Association. Patty and Michele shared invaluable insights into the daily realities of living with #hypoparathyroidism. Their perspectives underscored the importance of our work and deepened our commitment to making a difference for patients impacted by this challenging condition. At MBX, our mission is to help people with #endocrine and #metabolic disorders live fuller and healthier lives.        Learn more about MBX and explore opportunities to join us in pursuit of this mission by visiting our LinkedIn Careers page: https://bit.ly/3C8NcDc 

The MBX team is participating in three investor conferences this November, including the Guggenheim Inaugural Healthcare Innovation Conference, the Stifel Healthcare Conference and the Jefferies London Healthcare Conference. View full details below and access the live webcasts and replays on our IR site. https://lnkd.in/ebwYDuWq #JefferiesHealthcare

This week, we presented the rationale and design of the Phase 2 Avail™ trial of MBX 2109, our potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with #hypoparathyroidism (HP) at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting.   Engineered by our proprietary Precision Endocrine Peptide™(PEP™) technology, MBX 2109 is designed to help patients with hypoparathyroidism achieve continuous and consistent PTH exposure to improve total health outcomes and reduce dosing frequency.   We look forward to future developments in our pipeline of PEPs as we continue to push the boundaries of innovation to help people with #endocrine and #metabolic disorders live fuller and healthier lives. Read the full release here: https://lnkd.in/efuK2zVF   #ASBMR2024

Thank you Nasdaq for hosting us this morning to ring the Opening Bell! We appreciate everyone who made it possible for us to share this incredible honor with our friends, employees and partners both virtually and in person.

We are proud to announce that the first patient has been dosed in our Phase 2 AvailTM trial evaluating MBX 2109, our parathyroid hormone (PTH) peptide prodrug that is designed to be long-acting and is in development for the treatment of chronic #hypoparathyroidism (HP). Leveraging our proprietary Precision Endocrine PeptideTM (PEPTM) platform technology, MBX 2109 is designed to provide convenient, once-weekly administration and a continuous, infusion-like PTH exposure with lower daily peak-to-trough ratios than observed with daily PTH dosing regimens. With this milestone, we move forward in our mission to support those with #endocrine disorders in leading fuller and healthier lives. Learn more:https://lnkd.in/e3GJxF2w

We are proud to announce that the first patient has been dosed in our Phase 2 AvailTM trial evaluating MBX 2109, our parathyroid hormone (PTH) peptide prodrug that is designed to be long-acting and is in development for the treatment of chronic #hypoparathyroidism (HP). Leveraging our proprietary Precision Endocrine PeptideTM (PEPTM) platform technology, MBX 2109 is designed to provide convenient, once-weekly administration and a continuous, infusion-like PTH exposure with lower daily peak-to-trough ratios than observed with daily PTH dosing regimens. With this milestone, we move forward in our mission to support those with #endocrine disorders in leading fuller and healthier lives. Learn more:https://lnkd.in/e3GJxF2w

We’re proud to announce the completion of a $63.5 million Series C financing round. Funds will go towards supporting our ongoing Phase 2 clinical study of MBX-2109 in #hypoparathyroidism and accelerating our early-stage pipeline programs for the treatment of #endocrine and #metabolic disorders. Learn more about the news and our commitment to making a meaningful impact in the lives of these patients: https://lnkd.in/eSTR5Jnf  

We are proud to share that our Chief Executive Officer and Co-Founder, Kent Hawryluk, and Scientific Co-Founder, Richard DiMarchi, Ph.D., have been named to the 2024 Indiana 250: a list of the state’s most influential and impactful business and community leaders! This recognition from IBJ Media, Indianapolis Business Journal, and Inside INdiana Business recognizes their outstanding leadership, vision, and contributions to therapeutic innovation to improve patient lives throughout our communities and beyond. Join us in congratulating Kent and Dr. DiMarchi on this prestigious honor! See the full list here: https://bit.ly/3W7c3xE  #Indiana250

We’re thrilled to announce the appointment of Salomon (Sam) Azoulay, M.D., as Chief Medical Officer of MBX Biosciences! Dr. Azoulay’s extensive expertise in drug development and operations will be an invaluable asset to our team, where he will oversee MBX’s global clinical development pipeline as we progress our precision peptide candidates for the treatment of endocrine and metabolic disorders. Learn more about Dr. Azoulay and read the full release here: https://bit.ly/4cEL2ID

Today, on #WorldHypoparathyroidismDay, we stand with the estimated 250,000+ people worldwide living with #hypoparathyroidism (HP). At MBX Biosciences, we recognize the significance of today and the profound impact HP has on individuals and communities worldwide. Through our ongoing efforts with the HypoPARAthyroidism Association, we strive to raise awareness, drive meaningful change and create a more inclusive and compassionate community for these individuals. Join us today and every day as we stand with HP patients worldwide. Together, we can make a difference.